Day 2 Recap: Fall Clinical 2024

Author(s):

Emma Andrus, Associate Editor

Key Takeaways

Upadacitinib outperformed Dupilumab in achieving higher treatment targets for atopic dermatitis patients in the LEVEL UP Period 2 study.
Guselkumab demonstrated significant efficacy in clearing moderate psoriasis in patients unresponsive to topical treatments.
James Del Rosso, DO, reviewed current and upcoming monoclonal antibodies, including nemolizumab and lebrikizumab.
Mona Shahriari, MD, highlighted advanced treatments and clinical trial inclusivity for complex skin conditions at Fall Clinical 2024.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

New LEVEL UP Period 2 Data Shows Patients Who Switched From Dupilumab to Upadacitinib Achieved Higher Treatment Targets in AD

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Guselkumab Demonstrates Significant Skin Clearance in Hard-to-Treat Moderate Psoriasis Sites

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

The Latest in Dermatology With James Del Rosso, DO: Part 2

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Game-Changing Insights on Itch, Psoriatic Disease, and Innovations With Mona Shahriari, MD, FAAD

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis

Shawn Kwatra, MD, reviews key highlights of his sessions at Fall Clinical 2024 on the latest updates in itch conditions.

To view all conference coverage from Fall Clinical 2024, click here.